Legend Co-Leads $38M Round In Chinese Medical CRO Firm Bellen

For Digital Subscribers Only

Legend Capital and Zhongjinqichen, a healthcare, technology and consumer-focused private equity fund under China International Capital Co., Ltd have lead a RMB250 million (US$38 million) series B round in Bellen, a Chinese medical contract research organization (CRO).

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

RELATED NEWS



LEAVE A REPLY